In line with these latter findings, we indicate a high expression of PLK3 to significantly correlate with improved distant tumor control and long-term survival (Figure 2) in a CSCC cohort treated with definitive CRT plus BT, supporting its proposed tumor suppressor activity. Here, PLK3 is linked to neoplasm.